Clinical Trials · NCT04576455

A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)

Name: A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

Active Not RecruitingPhase 2Gonadorelin

Phase: Phase 2
Recruitment status: Active Not Recruiting
Sponsor: Hoffmann-La Roche
Enrollment: 303
Start date: Nov 2020
Locations: 81 sites, 17 countries
Primary endpoint: Progression-Free Survival (PFS), as Determined by the Investigator According to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1)

View Gonadorelin compound reference